Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,343.72
(
-0.39%
)
US TECH 100
22,535.60
(
0.92%
)
Dow Jones
45,216.14
(
0.11%
)
Brent Oil
106.83
(
-1.61%
)
Bitcoin
66,380.00
(
-0.48%
)
News Focus
News Focus
Post# of 257314
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122824
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 247743

Tuesday, 06/27/2023 9:38:36 PM

Tuesday, June 27, 2023 9:38:36 PM

Post# of 257314
Hanmi Pharma* is_running_a_phase-2 NASH trial_with HM15211—which_has_the_same_triple-agonist_MoA as LLY’s Retatrutide:

https://www.clinicaltrials.gov/study/NCT04505436

Trial sites are mostly in the US with a few in South Korea. The listed primary-completion date is May 2025.

Hitting three targets may not be the best way to go, due to the kinds of safety/tolerability issues described in #msg-172222042.

*Private company based in Korea.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today